Labcorp Holdings Inc. announced the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment of Alzheimer's disease in primary care settings. The test is designed to help clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathology. This regulatory approval allows the test to be performed via a simple blood draw in doctor's offices or Labcorp's patient service centers, providing an alternative to traditional, more invasive diagnostic methods.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.